Safety Profile and Clinical and Virological Outcomes of Nirmatrelvir-Ritonavir Treatment in Patients With Advanced Chronic Kidney Disease and Coronavirus Disease 2019
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
BACKGROUND: Nirmatrelvir-ritonavir is currently not recommended in patients with an estimated glomerular filtration rate (eGFR) <30 mL/minute/1.73 m2.
METHODS: To determine the safety profile and clinical and virological outcomes of nirmatrelvir-ritonavir use at a modified dosage in adults with chronic kidney disease (CKD), a prospective, single-arm, interventional trial recruited patients with eGFR <30 mL/minute/1.73 m2 and on dialysis. Primary outcomes included safety profile, adverse/serious adverse events, and events leading to drug discontinuation. Disease symptoms, virological outcomes by serial severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral polymerase chain reaction (PCR) tests, rapid antigen tests, and virological and symptomatic rebound were also recorded.
RESULTS: Fifty-nine (69.4%) of the 85 participants had stage 5 CKD and were on dialysis. Eighty (94.1%) completed the full treatment course; 9.4% and 5.9% had adverse and serious adverse events, and these were comparable between those with eGFR < or >30 mL/minute/1.73 m2. The viral load significantly decreased on days 5, 15, and 30 (P < .001 for all), and the reduction was consistent in the subgroup with eGFR <30 mL/minute/1.73 m2. Ten patients had virological rebound, which was transient and asymptomatic.
CONCLUSIONS: Among patients with CKD, a modified dose of nirmatrelvir-ritonavir is a well-tolerated therapy in mild COVID-19 as it can effectively suppress the SARS-CoV-2 viral load with a favorable safety profile. Virological and symptomatic rebound, although transient with low infectivity, may occur after treatment. Nirmatrelvir-ritonavir should be considered for use in patients with CKD, including stage 5 CKD on dialysis. Clinical Trials Registration. Clinical Trials.gov; identifier: NCT05624840.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:77 |
---|---|
Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 77(2023), 10 vom: 17. Nov., Seite 1406-1412 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Chan, Gordon Chun Kau [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 14.02.2024 Date Revised 29.03.2024 published: Print ClinicalTrials.gov: NCT05624840 Citation Status MEDLINE |
---|
doi: |
10.1093/cid/ciad371 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM360308430 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM360308430 | ||
003 | DE-627 | ||
005 | 20240331000637.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1093/cid/ciad371 |2 doi | |
028 | 5 | 2 | |a pubmed24n1357.xml |
035 | |a (DE-627)NLM360308430 | ||
035 | |a (NLM)37531093 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Chan, Gordon Chun Kau |e verfasserin |4 aut | |
245 | 1 | 0 | |a Safety Profile and Clinical and Virological Outcomes of Nirmatrelvir-Ritonavir Treatment in Patients With Advanced Chronic Kidney Disease and Coronavirus Disease 2019 |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 14.02.2024 | ||
500 | |a Date Revised 29.03.2024 | ||
500 | |a published: Print | ||
500 | |a ClinicalTrials.gov: NCT05624840 | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
520 | |a BACKGROUND: Nirmatrelvir-ritonavir is currently not recommended in patients with an estimated glomerular filtration rate (eGFR) <30 mL/minute/1.73 m2 | ||
520 | |a METHODS: To determine the safety profile and clinical and virological outcomes of nirmatrelvir-ritonavir use at a modified dosage in adults with chronic kidney disease (CKD), a prospective, single-arm, interventional trial recruited patients with eGFR <30 mL/minute/1.73 m2 and on dialysis. Primary outcomes included safety profile, adverse/serious adverse events, and events leading to drug discontinuation. Disease symptoms, virological outcomes by serial severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral polymerase chain reaction (PCR) tests, rapid antigen tests, and virological and symptomatic rebound were also recorded | ||
520 | |a RESULTS: Fifty-nine (69.4%) of the 85 participants had stage 5 CKD and were on dialysis. Eighty (94.1%) completed the full treatment course; 9.4% and 5.9% had adverse and serious adverse events, and these were comparable between those with eGFR < or >30 mL/minute/1.73 m2. The viral load significantly decreased on days 5, 15, and 30 (P < .001 for all), and the reduction was consistent in the subgroup with eGFR <30 mL/minute/1.73 m2. Ten patients had virological rebound, which was transient and asymptomatic | ||
520 | |a CONCLUSIONS: Among patients with CKD, a modified dose of nirmatrelvir-ritonavir is a well-tolerated therapy in mild COVID-19 as it can effectively suppress the SARS-CoV-2 viral load with a favorable safety profile. Virological and symptomatic rebound, although transient with low infectivity, may occur after treatment. Nirmatrelvir-ritonavir should be considered for use in patients with CKD, including stage 5 CKD on dialysis. Clinical Trials Registration. Clinical Trials.gov; identifier: NCT05624840 | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a chronic kidney disease | |
650 | 4 | |a dialysis | |
650 | 4 | |a nirmatrelvir-ritonavir | |
650 | 4 | |a rebound | |
650 | 7 | |a nirmatrelvir |2 NLM | |
650 | 7 | |a 7R9A5P7H32 |2 NLM | |
650 | 7 | |a Ritonavir |2 NLM | |
650 | 7 | |a O3J8G9O825 |2 NLM | |
650 | 7 | |a Antiviral Agents |2 NLM | |
650 | 7 | |a Lactams |2 NLM | |
650 | 7 | |a Leucine |2 NLM | |
650 | 7 | |a GMW67QNF9C |2 NLM | |
650 | 7 | |a Nitriles |2 NLM | |
650 | 7 | |a Proline |2 NLM | |
650 | 7 | |a 9DLQ4CIU6V |2 NLM | |
700 | 1 | |a Lui, Grace Chung Yan |e verfasserin |4 aut | |
700 | 1 | |a Wong, Candy Ngai Sze |e verfasserin |4 aut | |
700 | 1 | |a Yip, Sindy Sin Ting |e verfasserin |4 aut | |
700 | 1 | |a Li, Timothy Chun Man |e verfasserin |4 aut | |
700 | 1 | |a Cheung, Catherine Siu King |e verfasserin |4 aut | |
700 | 1 | |a Sze, Ryan Kin Ho |e verfasserin |4 aut | |
700 | 1 | |a Szeto, Cheuk Chun |e verfasserin |4 aut | |
700 | 1 | |a Chow, Kai Ming |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 77(2023), 10 vom: 17. Nov., Seite 1406-1412 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
773 | 1 | 8 | |g volume:77 |g year:2023 |g number:10 |g day:17 |g month:11 |g pages:1406-1412 |
856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciad371 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 77 |j 2023 |e 10 |b 17 |c 11 |h 1406-1412 |